The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
暂无分享,去创建一个
Nelson B Rodrigues | R. McIntyre | J. Rosenblat | E. Brietzke | R. Mansur | A. Abrishami | Yena Lee | Mehala Subramaniapillai | Lee Phan | E. Chau | Orly Lipsitz | F. Nasri | L. Lui | Isabelle P Carvalho | Amna Majeed | Ashley N. Siegel | Anil Arekapudi | Kevin Kratiuk | Witold Szpejda | H. Gill | Olena Senyk | Isabelle P. Carvalho
[1] N. McNaughton,et al. Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study , 2020, Journal of psychopharmacology.
[2] Y. Ning,et al. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. , 2019, Journal of affective disorders.
[3] D. Greenstein,et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. , 2019, Journal of affective disorders.
[4] Xiang Li,et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.
[5] R. Temple,et al. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class. , 2019, The New England journal of medicine.
[6] J. Talbot,et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. , 2019, The American journal of psychiatry.
[7] M. Fava,et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression , 2018, Depression and anxiety.
[8] D. M. Lyons,et al. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. , 2018, The American journal of psychiatry.
[9] P. Cuijpers,et al. Are studies of psychotherapies for depression more or less generalizable than studies of antidepressants? , 2018, Journal of affective disorders.
[10] M. Olfson,et al. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression , 2018, Journal of managed care & specialty pharmacy.
[11] L. Davidson,et al. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. , 2018, Journal of affective disorders.
[12] J. Mann,et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. , 2017, The American journal of psychiatry.
[13] Kelly C. Lee,et al. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. , 2017, Journal of affective disorders.
[14] E. Ballard,et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.
[15] T. Suppes,et al. Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. , 2017, The Journal of clinical psychiatry.
[16] C. Zorumski,et al. Use of Ketamine in Clinical Practice: A Time for Optimism and Caution. , 2017, JAMA psychiatry.
[17] M. Frye,et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders , 2017, JAMA psychiatry.
[18] L. Bartova,et al. Administration of ketamine for unipolar and bipolar depression , 2017, International journal of psychiatry in clinical practice.
[19] Daniel J. Müller,et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder , 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[20] C. Nemeroff,et al. WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN? , 2016, Depression and anxiety.
[21] E. Brown,et al. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study. , 2016, The Journal of clinical psychiatry.
[22] R. Shelton,et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. , 2016, The American journal of psychiatry.
[23] R. McIntyre,et al. A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect , 2016, Journal of clinical psychopharmacology.
[24] D. Luckenbaugh,et al. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. , 2015, Bipolar disorders.
[25] M. Frye,et al. Concomitant Benzodiazepine Use Attenuates Ketamine Response: Implications for Large Scale Study Design and Clinical Development , 2015, Journal of clinical psychopharmacology.
[26] K. Laws,et al. The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.
[27] R. Lam,et al. Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions , 2014, CNS Drugs.
[28] Dennis S. Charney,et al. Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression , 2013, Biological Psychiatry.
[29] Paul A. Harris,et al. Procurement of shared data instruments for Research Electronic Data Capture (REDCap) , 2013, J. Biomed. Informatics.
[30] F. Zitman,et al. Efficacy versus Effectiveness: A Direct Comparison of the Outcome of Treatment for Mild to Moderate Depression in Randomized Controlled Trials and Daily Practice , 2012, Psychotherapy and Psychosomatics.
[31] H. Möller,et al. Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. , 2010, The Journal of clinical psychiatry.
[32] D. Kupfer,et al. Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .
[33] B. Löwe,et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. , 2006, Archives of internal medicine.
[34] M. Gitlin. Treatment-resistant bipolar disorder , 2006, Molecular Psychiatry.
[35] M. Fava,et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D , 2004, Psychological Medicine.
[36] J. Markowitz,et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression , 2003, Biological Psychiatry.
[37] John H Krystal,et al. Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.
[38] A. Rush,et al. When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.
[39] C. Loo,et al. Side-effects associated with ketamine use in depression: a systematic review. , 2018, The lancet. Psychiatry.
[40] S. Southwick,et al. Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.